21 related articles for article (PubMed ID: 38581590)
1. Reproducibility of MRI Diagnosis of Female Genital Anomalies.
Elshetry ASF; Assy MM; Zaid NA; El-Fawakry RM; Radwan MHSS; Hamed EM
Can Assoc Radiol J; 2024 May; ():8465371241252793. PubMed ID: 38795028
[No Abstract] [Full Text] [Related]
2. Reply to "Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain Evidence".
de Oliveira Correia ET; Purysko AS; Paranhos BM; Shoag JE; Padhani AR; Bittencourt LK
AJR Am J Roentgenol; 2024 Mar; ():1. PubMed ID: 38506544
[No Abstract] [Full Text] [Related]
3. Prostate Cancer Screening and Prostate MRI: Hypotheses Founded on Uncertain Evidence.
Takahashi T
AJR Am J Roentgenol; 2024 Mar; ():1. PubMed ID: 38506539
[No Abstract] [Full Text] [Related]
4. Expected impact of MRI-related interreader variability on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R; Kilpeläinen TP; Kenttämies A; Ronkainen J; Ijäs K; Lind K; Marjasuo S; Oksala J; Oksanen O; Saarinen T; Savolainen R; Taari K; Tammela TLJ; Mirtti T; Natunen K; Auvinen A; Rannikko A
Cancer Imaging; 2020 Oct; 20(1):72. PubMed ID: 33036660
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Prostate Cancer in PI-RADS Version 2.1 Transition Zone Atypical Nodules Upgraded by Abnormal DWI: Correlation With MRI-Directed TRUS-Guided Targeted Biopsy.
Lim CS; Abreu-Gomez J; Carrion I; Schieda N
AJR Am J Roentgenol; 2021 Mar; 216(3):683-690. PubMed ID: 32755208
[No Abstract] [Full Text] [Related]
6. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI].
Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX
Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079
[No Abstract] [Full Text] [Related]
7. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men.
Chiu PK; Lam TY; Ng CF; Teoh JY; Cho CC; Hung HY; Hong C; Roobol MJ; Chu WC; Wong SY; Sung JJ
Asian J Androl; 2023 Nov; 25(6):674-679. PubMed ID: 37534902
[TBL] [Abstract][Full Text] [Related]
8. Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
Patel HD; Koehne EL; Shea SM; Fang AM; Gorbonos A; Quek ML; Flanigan RC; Goldberg A; Rais-Bahrami S; Gupta GN
J Urol; 2022 Jan; 207(1):108-117. PubMed ID: 34428091
[TBL] [Abstract][Full Text] [Related]
9. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in prostate cancer pathology: Gleason grading and beyond.
Shah RB; Zhou M
Pathol Int; 2016 May; 66(5):260-72. PubMed ID: 26991008
[TBL] [Abstract][Full Text] [Related]
11. Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study.
Hietikko R; Mirtti T; Kilpeläinen TP; Tolonen T; Räisänen-Sokolowski A; Nordling S; Hannus J; Laurila M; Taari K; Tammela TLJ; Autio R; Natunen K; Auvinen A; Rannikko A
World J Urol; 2024 Apr; 42(1):217. PubMed ID: 38581590
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
